Drug Eluting Implants Market - Forecasts from 2025 to 2030
Description
Drug Eluting Implants Market Size:
The Drug Eluting Implants Market is forecasted to advance from USD 7.561 billion in 2025 to USD 10.133 billion by 2030, at a CAGR of 6.03%.
The global drug-eluting implants market is poised for significant growth, driven by their ability to deliver controlled-release active pharmaceutical ingredients (APIs) directly to targeted tissues, enhancing treatment efficacy while minimizing side effects. These implants, notably drug-eluting stents (DES), outperform traditional oral or parenteral drug delivery methods and are increasingly adopted for managing conditions such as diabetes, cancer, contraception, HIV/AIDS prevention, chronic pain, cardiology, and central nervous system disorders. Key growth drivers include the rising prevalence of chronic diseases, an aging global population, and increased R&D investments. The market faces challenges from high development costs but benefits from growing patient adoption and technological advancements.
Market Drivers
Rising Prevalence of Diabetes
The global surge in diabetes cases is a major catalyst for the drug-eluting implants market. These implants are increasingly utilized for their healing properties in diabetes management, offering targeted drug delivery to improve patient outcomes. The International Diabetes Federation projects that the number of people with diabetes aged 20–79 will reach 700,002 by 2045, up significantly from previous years. This growing patient population is expected to drive demand for drug-eluting implants, as their precise delivery mechanisms support effective disease management, fueling market expansion through 2030.
Increasing Cancer Incidence
The rising global incidence of cancer significantly boosts the market for drug-eluting implants, particularly in chemotherapy applications. These implants provide a minimally invasive, image-guided parenteral route for drug administration, enhancing treatment precision. The increasing number of chemotherapy sessions worldwide, driven by growing cancer cases, underscores the demand for such implants. Their ability to deliver targeted therapies with reduced impact on healthy tissues positions them as a critical tool in oncology, further accelerating market growth during the forecast period.
Aging Population
The global geriatric population, projected by the United Nations to double to 1.5 billion by 2050, is a key driver. Older individuals are more prone to conditions requiring drug-eluting implants, such as cardiovascular diseases and cancer, increasing market demand. This demographic shift amplifies the need for advanced treatment options, positioning drug-eluting implants as a vital solution in addressing age-related health challenges.
Geographical Outlook
The Asia-Pacific region is expected to experience significant market growth, driven by its expanding geriatric population and rising prevalence of diabetes and cancer. North America and Europe continue to lead due to high adoption rates and advanced healthcare infrastructure, but Asia-Pacific’s rapid healthcare advancements and large patient base make it a high-growth region through 2030.
Competitive Landscape
Key players, including iVascular, ProMed Pharma, LLC, Johnson & Johnson, Boston Scientific Corporation, The Merck Group, Medtronic, Inc., Biosensors International Group, Abbott Laboratories, Elixir Medical Corporation, and Siemens Healthcare, are driving innovation through strategic partnerships and product development. For instance, in May 2023, iVascular received CE mark approval for its iCover balloon-expandable covered stent, enhancing vascular treatment options.
Market Outlook
The drug-eluting implants market is set for robust growth through 2030, propelled by rising chronic disease prevalence, an aging population, and R&D advancements. Asia-Pacific’s rapid expansion, alongside North America and Europe’s dominance, underscores the market’s global potential. Stakeholders must focus on innovation and scalability to meet growing demand while addressing cost-related challenges.
Key Benefits of this Report:
Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.
What do businesses use our reports for?
Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence
Report Coverage:
Historical data from 2022 to 2024 & forecast data from 2025 to 2030
Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
Competitive Positioning, Strategies, and Market Share Analysis
Revenue Growth and Forecast Assessment of segments and regions including countries
Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.
Market Segmentation:
By Product Type
Drug Eluting Stents
Contraceptive Implants
Drug Eluting Vascular Grafts
Others
By Material
Biodegradable
Non-Biodegradable
By Application
Oncology
Ophthalmology
Cardiology
Contraception/Birth Control
Others
By End-User
Hospital
Ambulatory Surgical Centers
Others
By Geography
North America
USA
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Israel
Others
Asia Pacific
China
India
Japan
South Korea
Indonesia
Thailand
Taiwan
Others
The Drug Eluting Implants Market is forecasted to advance from USD 7.561 billion in 2025 to USD 10.133 billion by 2030, at a CAGR of 6.03%.
The global drug-eluting implants market is poised for significant growth, driven by their ability to deliver controlled-release active pharmaceutical ingredients (APIs) directly to targeted tissues, enhancing treatment efficacy while minimizing side effects. These implants, notably drug-eluting stents (DES), outperform traditional oral or parenteral drug delivery methods and are increasingly adopted for managing conditions such as diabetes, cancer, contraception, HIV/AIDS prevention, chronic pain, cardiology, and central nervous system disorders. Key growth drivers include the rising prevalence of chronic diseases, an aging global population, and increased R&D investments. The market faces challenges from high development costs but benefits from growing patient adoption and technological advancements.
Market Drivers
Rising Prevalence of Diabetes
The global surge in diabetes cases is a major catalyst for the drug-eluting implants market. These implants are increasingly utilized for their healing properties in diabetes management, offering targeted drug delivery to improve patient outcomes. The International Diabetes Federation projects that the number of people with diabetes aged 20–79 will reach 700,002 by 2045, up significantly from previous years. This growing patient population is expected to drive demand for drug-eluting implants, as their precise delivery mechanisms support effective disease management, fueling market expansion through 2030.
Increasing Cancer Incidence
The rising global incidence of cancer significantly boosts the market for drug-eluting implants, particularly in chemotherapy applications. These implants provide a minimally invasive, image-guided parenteral route for drug administration, enhancing treatment precision. The increasing number of chemotherapy sessions worldwide, driven by growing cancer cases, underscores the demand for such implants. Their ability to deliver targeted therapies with reduced impact on healthy tissues positions them as a critical tool in oncology, further accelerating market growth during the forecast period.
Aging Population
The global geriatric population, projected by the United Nations to double to 1.5 billion by 2050, is a key driver. Older individuals are more prone to conditions requiring drug-eluting implants, such as cardiovascular diseases and cancer, increasing market demand. This demographic shift amplifies the need for advanced treatment options, positioning drug-eluting implants as a vital solution in addressing age-related health challenges.
Geographical Outlook
The Asia-Pacific region is expected to experience significant market growth, driven by its expanding geriatric population and rising prevalence of diabetes and cancer. North America and Europe continue to lead due to high adoption rates and advanced healthcare infrastructure, but Asia-Pacific’s rapid healthcare advancements and large patient base make it a high-growth region through 2030.
Competitive Landscape
Key players, including iVascular, ProMed Pharma, LLC, Johnson & Johnson, Boston Scientific Corporation, The Merck Group, Medtronic, Inc., Biosensors International Group, Abbott Laboratories, Elixir Medical Corporation, and Siemens Healthcare, are driving innovation through strategic partnerships and product development. For instance, in May 2023, iVascular received CE mark approval for its iCover balloon-expandable covered stent, enhancing vascular treatment options.
Market Outlook
The drug-eluting implants market is set for robust growth through 2030, propelled by rising chronic disease prevalence, an aging population, and R&D advancements. Asia-Pacific’s rapid expansion, alongside North America and Europe’s dominance, underscores the market’s global potential. Stakeholders must focus on innovation and scalability to meet growing demand while addressing cost-related challenges.
Key Benefits of this Report:
Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.
What do businesses use our reports for?
Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence
Report Coverage:
Historical data from 2022 to 2024 & forecast data from 2025 to 2030
Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
Competitive Positioning, Strategies, and Market Share Analysis
Revenue Growth and Forecast Assessment of segments and regions including countries
Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.
Market Segmentation:
By Product Type
Drug Eluting Stents
Contraceptive Implants
Drug Eluting Vascular Grafts
Others
By Material
Biodegradable
Non-Biodegradable
By Application
Oncology
Ophthalmology
Cardiology
Contraception/Birth Control
Others
By End-User
Hospital
Ambulatory Surgical Centers
Others
By Geography
North America
USA
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Israel
Others
Asia Pacific
China
India
Japan
South Korea
Indonesia
Thailand
Taiwan
Others
Table of Contents
148 Pages
- 1. EXECUTIVE SUMMARY
- 2. MARKET SNAPSHOT
- 2.1. Market Overview
- 2.2. Market Definition
- 2.3. Scope of the Study
- 2.4. Market Segmentation
- 3. BUSINESS LANDSCAPE
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Porter’s Five Forces Analysis
- 3.5. Industry Value Chain Analysis
- 3.6. Policies and Regulations
- 3.7. Strategic Recommendations
- 4. TECHNOLOGICAL OUTLOOK
- 5. DRUG ELUTING IMPLANTS MARKET BY PRODUCT TYPE
- 5.
- 1. Introduction
- 5.2. Drug Eluting Stents
- 5.3. Contraceptive Implants
- 5.4. Drug Eluting Vascular Grafts
- 5.5. Others
- 6. DRUG ELUTING IMPLANTS MARKET BY MATERIAL
- 6.
- 1. Introduction
- 6.2. Biodegradable
- 6.3. Non-Biodegradable
- 7. DRUG ELUTING IMPLANTS MARKET BY APPLICATION
- 7.
- 1. Introduction
- 7.2. Oncology
- 7.3. Opthalmology
- 7.4. Cardiology
- 7.5. Contraception/Birth Control
- 7.6. Others
- 8. DRUG ELUTING IMPLANTS MARKET BY END-USER
- 8.
- 1. Introduction
- 8.2. Hospital
- 8.3. Ambulatory Surgical Centers
- 8.4. Others
- 9. DRUG ELUTING IMPLANTS MARKET BY GEOGRAPHY
- 9.
- 1. Introduction
- 9.2. North America
- 9.2.1. USA
- 9.2.2. Canada
- 9.2.3. Mexico
- 9.3. South America
- 9.3.1. Brazil
- 9.3.2. Argentina
- 9.3.3. Others
- 9.4. Europe
- 9.4.1. Germany
- 9.4.2. France
- 9.4.3. United Kingdom
- 9.4.4. Italy
- 9.4.5. Spain
- 9.4.6. Others
- 9.5. Middle East and Africa
- 9.5.1. Saudi Arabia
- 9.5.2. UAE
- 9.5.3. Israel
- 9.5.4. Others
- 9.6. Asia Pacific
- 9.6.1. China
- 9.6.2. India
- 9.6.3. Japan
- 9.6.4. South Korea
- 9.6.5. Indonesia
- 9.6.6. Thailand
- 9.6.7. Taiwan
- 9.6.8. Others
- 10. COMPETITIVE ENVIRONMENT AND ANALYSIS
- 10.1. Major Players and Strategy Analysis
- 10.2. Market Share Analysis
- 10.3. Mergers, Acquisitions, Agreements, and Collaborations
- 10.4. Competitive Dashboard
- 11. COMPANY PROFILES
- 11.1. iVascular
- 11.2. ProMed Pharma
- 11.3. Boston Scientific Corporation
- 11.4. Merck Group
- 11.5. Medtronic, Inc.
- 11.6. Biosensors International Group
- 11.7. Abbott Laboratories
- 11.8. Elixir Medical Corporation
- 11.9. Biotronik SE & Co. KG
- 11.10. Lubrizol
- 12. APPENDIX
- 12.1. Currency
- 12.2. Assumptions
- 12.3. Base and Forecast Years Timeline
- 12.4. Key benefits for the stakeholders
- 12.5. Research Methodology
- 12.6. Abbreviations
- LIST OF FIGURES
- LIST OF TABLES
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
